Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03598998 · OUTCOME

Number of Participants Who Had Complete Response (CR)

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · Source last updated 2026-05-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 43 months after the initial study treatment.

What was measured

Number of participants who had a documented complete response at any time during study treatment. Disease response/progression by PET-CT or CT was evaluated using 2014 Lugano Classification.

Groups in this outcome

Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m2

Patients receive pralatrexate 20mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m2

Patients receive pralatrexate 30mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m27
Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m26

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m21Not reportedNot reportedNot reportedNot reported
Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m21Not reportedNot reportedNot reportedNot reported
Complete source fields
calculate Pct
false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    2. group Id
      OG001
      value
      6
    units
    Participants
description
Number of participants who had a documented complete response at any time during study treatment. Disease response/progression by PET-CT or CT was evaluated using 2014 Lugano Classification.
groups
  1. description
    Patients receive pralatrexate 20mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Phase I - Dose Level 1: Pembrolizumab 200mg + Pralatrexate 20mg/m2
  2. description
    Patients receive pralatrexate 30mg/m2 IV over 3-5 minutes on days 1 and 8 and pembrolizumab 200mg IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Phase I - Dose Level 2: Pembrolizumab 200mg + Pralatrexate 30mg/m2
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 43 months after the initial study treatment.
title
Number of Participants Who Had Complete Response (CR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice